Comparison of Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With Insulin-Treated Versus Non-Insulin Treated Diabetes Mellitus.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 11 11 2020
revised: 17 02 2021
accepted: 23 02 2021
pubmed: 6 3 2021
medline: 20 7 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

There are conflicting data on whether patients with insulin-treated diabetes mellitus (ITDM) have poorer outcomes compared with non-insulin treated diabetic (non-ITDM) patients following percutaneous coronary intervention (PCI). We therefore compared clinical outcomes following PCI in ITDM versus non-ITDM patients. We prospectively collected data on 4,579 patients with diabetes underwent PCI between 2005 and 2014 in a large multicenter registry and dichotomized them as having ITDM (n = 1,111) or non-ITDM (n = 3,468). The non-ITDM group was further divided into diet control only (diet-DM; n = 786) and those taking oral hypoglycemic agents (OHG-DM; n = 2,639), and clinical outcomes were compared with ITDM patients. Median follow-up for long-term mortality was 4.2 years (IQR 2.0 to 6.6 years). ITDM patients were more likely to be female, obese, and have severe renal impairment (all p <0.001). Procedural characteristics were similar other than a greater use of drug-eluting stents in ITDM patients. On multivariable analysis, ITDM was an independent predictor of 12-month major adverse cardiovascular and cerebrovascular events (MACCE; OR 1.26, 95% CI 1.02 to1.55, p = 0.03). Dividing the non-ITDM group further by treatment, a progressively higher rate of 12-month MACCE across the 3 groups was observed (13.5% vs 17.9% vs 21.8%; p <0.001). Long-term mortality was similar in the diet-DM and OHG-DM groups, but significantly higher in the ITDM group on Kaplan-Meier analysis (log-rank p <0.001). In conclusion, there is a clear gradient of adverse outcomes with escalation of therapy from diet control to OHGs to insulin.

Identifiants

pubmed: 33667454
pii: S0002-9149(21)00200-9
doi: 10.1016/j.amjcard.2021.02.025
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0
Insulin 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-43

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Sinjini Biswas (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

Diem Dinh (D)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Nick Andrianopoulos (N)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Jeffrey Lefkovits (J)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia.

Andrew Ajani (A)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.

Stephen J Duffy (SJ)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

William Chan (W)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

Antony Walton (A)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

Angela Brennan (A)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

David J Clark (DJ)

Department of Cardiology, Austin Health, Melbourne, Australia.

Chin Hiew (C)

Department of Cardiology, University Hospital Geelong, Geelong, Australia.

Ernesto Oqueli (E)

Department of Cardiology, Ballarat Health Services, Ballarat, Australia; School of Medicine, Deakin University, Ballarat, Australia.

Christopher M Reid (CM)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; School of Public Health, Curtin University, Perth, Australia.

Dion Stub (D)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

David Eccleston (D)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia. Electronic address: david.eccleston@mh.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH